27/01/23 (Agence Europe) – Following the meeting of its Committee for Medicinal Products for Human Use (CMPH) on 23-26 January, the European Medicines Agency (EMA) announced on Friday 27 January that it recommended converting the conditional marketing authorisation for Paxlovid, granted on 28 January 2022 by the European Commission (see EUROPE B12879A27), to a standard marketing authorisation. Paxlovid is an orally active antiviral drug composed of nirmatrelvir and ritonavir,...